nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Ezetimibe—atherosclerosis	0.103	0.267	CbGbCtD
Carfilzomib—ABCB1—Simvastatin—atherosclerosis	0.096	0.248	CbGbCtD
Carfilzomib—ABCB1—Lovastatin—atherosclerosis	0.0939	0.243	CbGbCtD
Carfilzomib—ABCB1—Pravastatin—atherosclerosis	0.0939	0.243	CbGbCtD
Carfilzomib—PSMB8—Fluvastatin—Rosuvastatin—atherosclerosis	0.0117	1	CbGdCrCtD
Carfilzomib—PSMB10—adipose tissue—atherosclerosis	0.00863	0.132	CbGeAlD
Carfilzomib—PSMB10—liver—atherosclerosis	0.00605	0.0925	CbGeAlD
Carfilzomib—PSMB8—adipose tissue—atherosclerosis	0.00556	0.085	CbGeAlD
Carfilzomib—PSMB2—connective tissue—atherosclerosis	0.00546	0.0834	CbGeAlD
Carfilzomib—PSMB5—adipose tissue—atherosclerosis	0.00491	0.075	CbGeAlD
Carfilzomib—Hepatic failure—Rosuvastatin—atherosclerosis	0.00488	0.0187	CcSEcCtD
Carfilzomib—PSMB1—cardiovascular system—atherosclerosis	0.00487	0.0744	CbGeAlD
Carfilzomib—PSMB2—cardiovascular system—atherosclerosis	0.00475	0.0726	CbGeAlD
Carfilzomib—Renal failure acute—Rosuvastatin—atherosclerosis	0.00475	0.0182	CcSEcCtD
Carfilzomib—PSMB1—adipose tissue—atherosclerosis	0.0043	0.0656	CbGeAlD
Carfilzomib—PSMB2—adipose tissue—atherosclerosis	0.00419	0.064	CbGeAlD
Carfilzomib—Hepatic failure—Lovastatin—atherosclerosis	0.00414	0.0159	CcSEcCtD
Carfilzomib—Hepatic failure—Ezetimibe—atherosclerosis	0.00406	0.0156	CcSEcCtD
Carfilzomib—PSMB8—liver—atherosclerosis	0.0039	0.0596	CbGeAlD
Carfilzomib—Hepatic failure—Simvastatin—atherosclerosis	0.00387	0.0149	CcSEcCtD
Carfilzomib—Pain in extremity—Lovastatin—atherosclerosis	0.00372	0.0143	CcSEcCtD
Carfilzomib—Pain in extremity—Ezetimibe—atherosclerosis	0.00365	0.014	CcSEcCtD
Carfilzomib—Hepatic failure—Pravastatin—atherosclerosis	0.0035	0.0134	CcSEcCtD
Carfilzomib—PSMB5—liver—atherosclerosis	0.00345	0.0526	CbGeAlD
Carfilzomib—Renal failure acute—Pravastatin—atherosclerosis	0.0034	0.0131	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Rosuvastatin—atherosclerosis	0.00331	0.0127	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.00328	0.0126	CcSEcCtD
Carfilzomib—PSMB1—liver—atherosclerosis	0.00301	0.046	CbGeAlD
Carfilzomib—PSMB2—liver—atherosclerosis	0.00294	0.0449	CbGeAlD
Carfilzomib—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.00293	0.0113	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Lovastatin—atherosclerosis	0.00281	0.0108	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.00279	0.0107	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.00275	0.0106	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Simvastatin—atherosclerosis	0.00263	0.0101	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00252	0.0097	CcSEcCtD
Carfilzomib—Oedema peripheral—Ezetimibe—atherosclerosis	0.00248	0.00954	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00239	0.00917	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Pravastatin—atherosclerosis	0.00237	0.00912	CcSEcCtD
Carfilzomib—Chills—Lovastatin—atherosclerosis	0.00231	0.00886	CcSEcCtD
Carfilzomib—Cough—Rosuvastatin—atherosclerosis	0.0023	0.00885	CcSEcCtD
Carfilzomib—Arthralgia—Rosuvastatin—atherosclerosis	0.00225	0.00864	CcSEcCtD
Carfilzomib—Hypoaesthesia—Niacin—atherosclerosis	0.0022	0.00844	CcSEcCtD
Carfilzomib—Oedema peripheral—Niacin—atherosclerosis	0.00218	0.00836	CcSEcCtD
Carfilzomib—Back pain—Lovastatin—atherosclerosis	0.00216	0.00832	CcSEcCtD
Carfilzomib—Hypoaesthesia—Pravastatin—atherosclerosis	0.00216	0.00831	CcSEcCtD
Carfilzomib—Chills—Simvastatin—atherosclerosis	0.00216	0.00829	CcSEcCtD
Carfilzomib—Muscle spasms—Lovastatin—atherosclerosis	0.00215	0.00827	CcSEcCtD
Carfilzomib—Infection—Rosuvastatin—atherosclerosis	0.00214	0.00823	CcSEcCtD
Carfilzomib—Back pain—Ezetimibe—atherosclerosis	0.00212	0.00816	CcSEcCtD
Carfilzomib—Muscle spasms—Ezetimibe—atherosclerosis	0.00211	0.00811	CcSEcCtD
Carfilzomib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00211	0.00811	CcSEcCtD
Carfilzomib—Anaemia—Ezetimibe—atherosclerosis	0.00203	0.0078	CcSEcCtD
Carfilzomib—Cardiac disorder—Pravastatin—atherosclerosis	0.00202	0.00775	CcSEcCtD
Carfilzomib—Muscle spasms—Simvastatin—atherosclerosis	0.00201	0.00773	CcSEcCtD
Carfilzomib—Leukopenia—Lovastatin—atherosclerosis	0.002	0.0077	CcSEcCtD
Carfilzomib—Chills—Niacin—atherosclerosis	0.00198	0.00761	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00196	0.00754	CcSEcCtD
Carfilzomib—Chills—Pravastatin—atherosclerosis	0.00195	0.0075	CcSEcCtD
Carfilzomib—Insomnia—Rosuvastatin—atherosclerosis	0.00195	0.00749	CcSEcCtD
Carfilzomib—Anaemia—Simvastatin—atherosclerosis	0.00193	0.00743	CcSEcCtD
Carfilzomib—Cough—Ezetimibe—atherosclerosis	0.00192	0.00736	CcSEcCtD
Carfilzomib—Arthralgia—Lovastatin—atherosclerosis	0.00191	0.00732	CcSEcCtD
Carfilzomib—Hypertension—Ezetimibe—atherosclerosis	0.0019	0.00728	CcSEcCtD
Carfilzomib—Leukopenia—Simvastatin—atherosclerosis	0.00187	0.0072	CcSEcCtD
Carfilzomib—Arthralgia—Ezetimibe—atherosclerosis	0.00187	0.00718	CcSEcCtD
Carfilzomib—Muscle spasms—Niacin—atherosclerosis	0.00185	0.0071	CcSEcCtD
Carfilzomib—Pain—Rosuvastatin—atherosclerosis	0.00184	0.00708	CcSEcCtD
Carfilzomib—Constipation—Rosuvastatin—atherosclerosis	0.00184	0.00708	CcSEcCtD
Carfilzomib—Muscle spasms—Pravastatin—atherosclerosis	0.00182	0.00699	CcSEcCtD
Carfilzomib—Infection—Lovastatin—atherosclerosis	0.00181	0.00697	CcSEcCtD
Carfilzomib—Thrombocytopenia—Lovastatin—atherosclerosis	0.00179	0.00687	CcSEcCtD
Carfilzomib—Arthralgia—Simvastatin—atherosclerosis	0.00178	0.00685	CcSEcCtD
Carfilzomib—Infection—Ezetimibe—atherosclerosis	0.00178	0.00684	CcSEcCtD
Carfilzomib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00175	0.00674	CcSEcCtD
Carfilzomib—Anaemia—Pravastatin—atherosclerosis	0.00175	0.00672	CcSEcCtD
Carfilzomib—Anorexia—Lovastatin—atherosclerosis	0.00174	0.00669	CcSEcCtD
Carfilzomib—Leukopenia—Niacin—atherosclerosis	0.00172	0.00661	CcSEcCtD
Carfilzomib—Infection—Simvastatin—atherosclerosis	0.0017	0.00652	CcSEcCtD
Carfilzomib—Leukopenia—Pravastatin—atherosclerosis	0.00169	0.00651	CcSEcCtD
Carfilzomib—Cough—Niacin—atherosclerosis	0.00168	0.00644	CcSEcCtD
Carfilzomib—Thrombocytopenia—Simvastatin—atherosclerosis	0.00167	0.00643	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00166	0.00639	CcSEcCtD
Carfilzomib—Insomnia—Lovastatin—atherosclerosis	0.00165	0.00635	CcSEcCtD
Carfilzomib—Cough—Pravastatin—atherosclerosis	0.00165	0.00635	CcSEcCtD
Carfilzomib—Arthralgia—Niacin—atherosclerosis	0.00164	0.00629	CcSEcCtD
Carfilzomib—Hypertension—Pravastatin—atherosclerosis	0.00163	0.00628	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00163	0.00627	CcSEcCtD
Carfilzomib—Anorexia—Simvastatin—atherosclerosis	0.00163	0.00626	CcSEcCtD
Carfilzomib—Dyspnoea—Lovastatin—atherosclerosis	0.00163	0.00626	CcSEcCtD
Carfilzomib—ABCB1—blood vessel—atherosclerosis	0.00163	0.0249	CbGeAlD
Carfilzomib—Insomnia—Ezetimibe—atherosclerosis	0.00162	0.00623	CcSEcCtD
Carfilzomib—Arthralgia—Pravastatin—atherosclerosis	0.00161	0.00619	CcSEcCtD
Carfilzomib—Dyspnoea—Ezetimibe—atherosclerosis	0.0016	0.00614	CcSEcCtD
Carfilzomib—Decreased appetite—Lovastatin—atherosclerosis	0.00159	0.0061	CcSEcCtD
Carfilzomib—Fatigue—Lovastatin—atherosclerosis	0.00157	0.00605	CcSEcCtD
Carfilzomib—Pain—Lovastatin—atherosclerosis	0.00156	0.006	CcSEcCtD
Carfilzomib—Constipation—Lovastatin—atherosclerosis	0.00156	0.006	CcSEcCtD
Carfilzomib—Decreased appetite—Ezetimibe—atherosclerosis	0.00156	0.00598	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00156	0.00598	CcSEcCtD
Carfilzomib—Asthenia—Rosuvastatin—atherosclerosis	0.00155	0.00594	CcSEcCtD
Carfilzomib—Insomnia—Simvastatin—atherosclerosis	0.00155	0.00594	CcSEcCtD
Carfilzomib—Fatigue—Ezetimibe—atherosclerosis	0.00154	0.00593	CcSEcCtD
Carfilzomib—Infection—Pravastatin—atherosclerosis	0.00153	0.0059	CcSEcCtD
Carfilzomib—Pain—Ezetimibe—atherosclerosis	0.00153	0.00589	CcSEcCtD
Carfilzomib—Constipation—Ezetimibe—atherosclerosis	0.00153	0.00589	CcSEcCtD
Carfilzomib—Dyspnoea—Simvastatin—atherosclerosis	0.00152	0.00585	CcSEcCtD
Carfilzomib—Thrombocytopenia—Pravastatin—atherosclerosis	0.00151	0.00581	CcSEcCtD
Carfilzomib—Anorexia—Niacin—atherosclerosis	0.0015	0.00575	CcSEcCtD
Carfilzomib—Decreased appetite—Simvastatin—atherosclerosis	0.00149	0.00571	CcSEcCtD
Carfilzomib—Diarrhoea—Rosuvastatin—atherosclerosis	0.00147	0.00567	CcSEcCtD
Carfilzomib—Fatigue—Simvastatin—atherosclerosis	0.00147	0.00566	CcSEcCtD
Carfilzomib—Anorexia—Pravastatin—atherosclerosis	0.00147	0.00566	CcSEcCtD
Carfilzomib—Pain—Simvastatin—atherosclerosis	0.00146	0.00561	CcSEcCtD
Carfilzomib—Constipation—Simvastatin—atherosclerosis	0.00146	0.00561	CcSEcCtD
Carfilzomib—Body temperature increased—Lovastatin—atherosclerosis	0.00144	0.00555	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00143	0.00549	CcSEcCtD
Carfilzomib—Dizziness—Rosuvastatin—atherosclerosis	0.00143	0.00548	CcSEcCtD
Carfilzomib—Insomnia—Niacin—atherosclerosis	0.00142	0.00545	CcSEcCtD
Carfilzomib—Body temperature increased—Ezetimibe—atherosclerosis	0.00142	0.00544	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00141	0.00541	CcSEcCtD
Carfilzomib—Dyspnoea—Niacin—atherosclerosis	0.0014	0.00537	CcSEcCtD
Carfilzomib—Insomnia—Pravastatin—atherosclerosis	0.0014	0.00537	CcSEcCtD
Carfilzomib—Dyspnoea—Pravastatin—atherosclerosis	0.00138	0.00529	CcSEcCtD
Carfilzomib—Decreased appetite—Niacin—atherosclerosis	0.00136	0.00524	CcSEcCtD
Carfilzomib—Body temperature increased—Simvastatin—atherosclerosis	0.00135	0.00519	CcSEcCtD
Carfilzomib—Headache—Rosuvastatin—atherosclerosis	0.00135	0.00519	CcSEcCtD
Carfilzomib—Decreased appetite—Pravastatin—atherosclerosis	0.00134	0.00516	CcSEcCtD
Carfilzomib—Pain—Niacin—atherosclerosis	0.00134	0.00515	CcSEcCtD
Carfilzomib—Fatigue—Pravastatin—atherosclerosis	0.00133	0.00512	CcSEcCtD
Carfilzomib—Pain—Pravastatin—atherosclerosis	0.00132	0.00508	CcSEcCtD
Carfilzomib—Constipation—Pravastatin—atherosclerosis	0.00132	0.00508	CcSEcCtD
Carfilzomib—Asthenia—Lovastatin—atherosclerosis	0.00131	0.00504	CcSEcCtD
Carfilzomib—Asthenia—Ezetimibe—atherosclerosis	0.00129	0.00494	CcSEcCtD
Carfilzomib—Nausea—Rosuvastatin—atherosclerosis	0.00128	0.00492	CcSEcCtD
Carfilzomib—Diarrhoea—Lovastatin—atherosclerosis	0.00125	0.0048	CcSEcCtD
Carfilzomib—Body temperature increased—Niacin—atherosclerosis	0.00124	0.00476	CcSEcCtD
Carfilzomib—Asthenia—Simvastatin—atherosclerosis	0.00123	0.00471	CcSEcCtD
Carfilzomib—Diarrhoea—Ezetimibe—atherosclerosis	0.00123	0.00471	CcSEcCtD
Carfilzomib—Body temperature increased—Pravastatin—atherosclerosis	0.00122	0.00469	CcSEcCtD
Carfilzomib—Dizziness—Lovastatin—atherosclerosis	0.00121	0.00464	CcSEcCtD
Carfilzomib—Dizziness—Ezetimibe—atherosclerosis	0.00118	0.00455	CcSEcCtD
Carfilzomib—Diarrhoea—Simvastatin—atherosclerosis	0.00117	0.00449	CcSEcCtD
Carfilzomib—Vomiting—Lovastatin—atherosclerosis	0.00116	0.00446	CcSEcCtD
Carfilzomib—Headache—Lovastatin—atherosclerosis	0.00114	0.0044	CcSEcCtD
Carfilzomib—Vomiting—Ezetimibe—atherosclerosis	0.00114	0.00438	CcSEcCtD
Carfilzomib—Dizziness—Simvastatin—atherosclerosis	0.00113	0.00434	CcSEcCtD
Carfilzomib—Asthenia—Niacin—atherosclerosis	0.00113	0.00432	CcSEcCtD
Carfilzomib—Headache—Ezetimibe—atherosclerosis	0.00112	0.00431	CcSEcCtD
Carfilzomib—Asthenia—Pravastatin—atherosclerosis	0.00111	0.00426	CcSEcCtD
Carfilzomib—Vomiting—Simvastatin—atherosclerosis	0.00109	0.00417	CcSEcCtD
Carfilzomib—Nausea—Lovastatin—atherosclerosis	0.00108	0.00417	CcSEcCtD
Carfilzomib—Diarrhoea—Niacin—atherosclerosis	0.00107	0.00412	CcSEcCtD
Carfilzomib—Headache—Simvastatin—atherosclerosis	0.00107	0.00411	CcSEcCtD
Carfilzomib—Nausea—Ezetimibe—atherosclerosis	0.00106	0.00409	CcSEcCtD
Carfilzomib—Diarrhoea—Pravastatin—atherosclerosis	0.00106	0.00406	CcSEcCtD
Carfilzomib—Dizziness—Niacin—atherosclerosis	0.00104	0.00399	CcSEcCtD
Carfilzomib—Dizziness—Pravastatin—atherosclerosis	0.00102	0.00392	CcSEcCtD
Carfilzomib—Nausea—Simvastatin—atherosclerosis	0.00101	0.0039	CcSEcCtD
Carfilzomib—Vomiting—Niacin—atherosclerosis	0.000997	0.00383	CcSEcCtD
Carfilzomib—Headache—Niacin—atherosclerosis	0.000983	0.00378	CcSEcCtD
Carfilzomib—Vomiting—Pravastatin—atherosclerosis	0.000982	0.00377	CcSEcCtD
Carfilzomib—Headache—Pravastatin—atherosclerosis	0.000968	0.00372	CcSEcCtD
Carfilzomib—Nausea—Niacin—atherosclerosis	0.000932	0.00358	CcSEcCtD
Carfilzomib—Nausea—Pravastatin—atherosclerosis	0.000917	0.00353	CcSEcCtD
Carfilzomib—ABCB1—cardiovascular system—atherosclerosis	0.000726	0.0111	CbGeAlD
Carfilzomib—ABCB1—adipose tissue—atherosclerosis	0.00064	0.00978	CbGeAlD
Carfilzomib—ABCB1—liver—atherosclerosis	0.000449	0.00686	CbGeAlD
Carfilzomib—PSMB1—Signaling Pathways—APOE—atherosclerosis	5.52e-05	0.0002	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—APOE—atherosclerosis	5.52e-05	0.0002	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—LEP—atherosclerosis	5.52e-05	0.0002	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CAV1—atherosclerosis	5.47e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CAV1—atherosclerosis	5.47e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CAV1—atherosclerosis	5.47e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—APOA1—atherosclerosis	5.46e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—APOA1—atherosclerosis	5.46e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—APOA1—atherosclerosis	5.46e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NOS3—atherosclerosis	5.46e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL1B—atherosclerosis	5.44e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL1B—atherosclerosis	5.44e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL1B—atherosclerosis	5.44e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—LEP—atherosclerosis	5.44e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—APOE—atherosclerosis	5.44e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NOS3—atherosclerosis	5.43e-05	0.000197	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	5.41e-05	0.000196	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTGS2—atherosclerosis	5.4e-05	0.000196	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTGS2—atherosclerosis	5.4e-05	0.000196	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PTGS2—atherosclerosis	5.4e-05	0.000196	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CAV1—atherosclerosis	5.39e-05	0.000196	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—APOA1—atherosclerosis	5.38e-05	0.000195	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL1B—atherosclerosis	5.37e-05	0.000195	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	5.33e-05	0.000194	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTGS2—atherosclerosis	5.33e-05	0.000193	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MAPK3—atherosclerosis	5.31e-05	0.000193	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MAPK3—atherosclerosis	5.29e-05	0.000192	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP27A1—atherosclerosis	5.29e-05	0.000192	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ESR1—atherosclerosis	5.27e-05	0.000191	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ESR1—atherosclerosis	5.27e-05	0.000191	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ESR1—atherosclerosis	5.27e-05	0.000191	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—F2—atherosclerosis	5.21e-05	0.000189	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—F2—atherosclerosis	5.21e-05	0.000189	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—F2—atherosclerosis	5.21e-05	0.000189	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ESR1—atherosclerosis	5.2e-05	0.000189	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—APOB—atherosclerosis	5.18e-05	0.000188	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	5.17e-05	0.000188	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—ALB—atherosclerosis	5.17e-05	0.000188	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—ALB—atherosclerosis	5.17e-05	0.000188	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—ALB—atherosclerosis	5.17e-05	0.000188	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—TGFB1—atherosclerosis	5.15e-05	0.000187	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—F2—atherosclerosis	5.13e-05	0.000186	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—TGFB1—atherosclerosis	5.13e-05	0.000186	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—ALB—atherosclerosis	5.1e-05	0.000185	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—NFKB1—atherosclerosis	5.08e-05	0.000184	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—NFKB1—atherosclerosis	5.08e-05	0.000184	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—NFKB1—atherosclerosis	5.08e-05	0.000184	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PLA2G2A—atherosclerosis	5.01e-05	0.000182	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOA2—atherosclerosis	5.01e-05	0.000182	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALOX15—atherosclerosis	5.01e-05	0.000182	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALOX5AP—atherosclerosis	5.01e-05	0.000182	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—NFKB1—atherosclerosis	5.01e-05	0.000182	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MAPK8—atherosclerosis	4.99e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MAPK8—atherosclerosis	4.99e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MAPK8—atherosclerosis	4.99e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CG—atherosclerosis	4.98e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CG—atherosclerosis	4.98e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CG—atherosclerosis	4.98e-05	0.000181	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ABCG5—atherosclerosis	4.95e-05	0.00018	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—NOS3—atherosclerosis	4.95e-05	0.000179	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—NOS3—atherosclerosis	4.95e-05	0.000179	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—NOS3—atherosclerosis	4.95e-05	0.000179	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MAPK8—atherosclerosis	4.92e-05	0.000179	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CG—atherosclerosis	4.91e-05	0.000178	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—NOS3—atherosclerosis	4.88e-05	0.000177	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—AKT1—atherosclerosis	4.85e-05	0.000176	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—AKT1—atherosclerosis	4.85e-05	0.000176	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—AKT1—atherosclerosis	4.85e-05	0.000176	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CXCL8—atherosclerosis	4.84e-05	0.000176	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	4.83e-05	0.000175	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CXCL8—atherosclerosis	4.82e-05	0.000175	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LPA—atherosclerosis	4.78e-05	0.000173	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—AKT1—atherosclerosis	4.78e-05	0.000173	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—INS—atherosclerosis	4.72e-05	0.000171	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—INS—atherosclerosis	4.72e-05	0.000171	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—INS—atherosclerosis	4.72e-05	0.000171	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—INS—atherosclerosis	4.65e-05	0.000169	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCL2—atherosclerosis	4.64e-05	0.000168	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCL2—atherosclerosis	4.64e-05	0.000168	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCL2—atherosclerosis	4.64e-05	0.000168	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—BGN—atherosclerosis	4.63e-05	0.000168	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOA5—atherosclerosis	4.58e-05	0.000166	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCL2—atherosclerosis	4.57e-05	0.000166	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—STAT3—atherosclerosis	4.56e-05	0.000166	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—STAT3—atherosclerosis	4.56e-05	0.000166	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—STAT3—atherosclerosis	4.56e-05	0.000166	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IGF1—atherosclerosis	4.56e-05	0.000166	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IGF1—atherosclerosis	4.56e-05	0.000166	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IGF1—atherosclerosis	4.56e-05	0.000166	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTGS2—atherosclerosis	4.52e-05	0.000164	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTGS2—atherosclerosis	4.52e-05	0.000164	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTGS2—atherosclerosis	4.52e-05	0.000164	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—STAT3—atherosclerosis	4.5e-05	0.000163	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IGF1—atherosclerosis	4.5e-05	0.000163	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTGS2—atherosclerosis	4.46e-05	0.000162	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PLA2G1B—atherosclerosis	4.41e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MMP9—atherosclerosis	4.38e-05	0.000159	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	4.37e-05	0.000159	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MAPK3—atherosclerosis	4.36e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MAPK3—atherosclerosis	4.36e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MAPK3—atherosclerosis	4.36e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP9—atherosclerosis	4.36e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MAPK3—atherosclerosis	4.34e-05	0.000157	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MAPK3—atherosclerosis	4.34e-05	0.000157	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MAPK3—atherosclerosis	4.34e-05	0.000157	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SERPINE1—atherosclerosis	4.33e-05	0.000157	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SERPINE1—atherosclerosis	4.33e-05	0.000157	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SERPINE1—atherosclerosis	4.33e-05	0.000157	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NFKB1—atherosclerosis	4.33e-05	0.000157	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NFKB1—atherosclerosis	4.31e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MAPK3—atherosclerosis	4.3e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MAPK3—atherosclerosis	4.27e-05	0.000155	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SERPINE1—atherosclerosis	4.27e-05	0.000155	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALOX5—atherosclerosis	4.26e-05	0.000155	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK8—atherosclerosis	4.26e-05	0.000155	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK8—atherosclerosis	4.24e-05	0.000154	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—STAT3—atherosclerosis	4.21e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—STAT3—atherosclerosis	4.21e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—STAT3—atherosclerosis	4.21e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—atherosclerosis	4.21e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—atherosclerosis	4.19e-05	0.000152	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—STAT3—atherosclerosis	4.15e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NOS3—atherosclerosis	4.14e-05	0.00015	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NOS3—atherosclerosis	4.14e-05	0.00015	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NOS3—atherosclerosis	4.14e-05	0.00015	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	4.1e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NOS3—atherosclerosis	4.08e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAPK3—atherosclerosis	4.02e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAPK3—atherosclerosis	4.02e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAPK3—atherosclerosis	4.02e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK3—atherosclerosis	3.97e-05	0.000144	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—atherosclerosis	3.93e-05	0.000143	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—atherosclerosis	3.91e-05	0.000142	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—atherosclerosis	3.91e-05	0.000142	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—atherosclerosis	3.91e-05	0.000142	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—atherosclerosis	3.91e-05	0.000142	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—atherosclerosis	3.89e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—atherosclerosis	3.88e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—atherosclerosis	3.88e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—atherosclerosis	3.87e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—atherosclerosis	3.86e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—atherosclerosis	3.86e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—atherosclerosis	3.86e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—atherosclerosis	3.85e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—atherosclerosis	3.84e-05	0.000139	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NAMPT—atherosclerosis	3.82e-05	0.000139	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LIPC—atherosclerosis	3.8e-05	0.000138	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOC3—atherosclerosis	3.77e-05	0.000137	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LDLR—atherosclerosis	3.75e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK3—atherosclerosis	3.72e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK3—atherosclerosis	3.7e-05	0.000134	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL8—atherosclerosis	3.67e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL8—atherosclerosis	3.67e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL8—atherosclerosis	3.67e-05	0.000133	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CETP—atherosclerosis	3.66e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL8—atherosclerosis	3.62e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—atherosclerosis	3.61e-05	0.000131	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	3.6e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—atherosclerosis	3.59e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—atherosclerosis	3.58e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—atherosclerosis	3.57e-05	0.000129	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SCARB1—atherosclerosis	3.51e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—atherosclerosis	3.32e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—atherosclerosis	3.32e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—atherosclerosis	3.32e-05	0.00012	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HMGCR—atherosclerosis	3.31e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NFKB1—atherosclerosis	3.28e-05	0.000119	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NFKB1—atherosclerosis	3.28e-05	0.000119	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NFKB1—atherosclerosis	3.28e-05	0.000119	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—atherosclerosis	3.27e-05	0.000119	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	3.25e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NFKB1—atherosclerosis	3.24e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK8—atherosclerosis	3.23e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK8—atherosclerosis	3.23e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK8—atherosclerosis	3.23e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—atherosclerosis	3.19e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—atherosclerosis	3.19e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—atherosclerosis	3.19e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK8—atherosclerosis	3.18e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—atherosclerosis	3.14e-05	0.000114	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—atherosclerosis	3e-05	0.000109	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—atherosclerosis	2.99e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—atherosclerosis	2.98e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—atherosclerosis	2.98e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—atherosclerosis	2.98e-05	0.000108	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ABCA1—atherosclerosis	2.95e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—atherosclerosis	2.95e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—atherosclerosis	2.95e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—atherosclerosis	2.95e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—atherosclerosis	2.94e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—atherosclerosis	2.94e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—atherosclerosis	2.94e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—atherosclerosis	2.94e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—atherosclerosis	2.94e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—atherosclerosis	2.94e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—atherosclerosis	2.94e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—atherosclerosis	2.92e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—atherosclerosis	2.92e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—atherosclerosis	2.92e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—atherosclerosis	2.91e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—atherosclerosis	2.9e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—atherosclerosis	2.9e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—atherosclerosis	2.88e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK3—atherosclerosis	2.82e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK3—atherosclerosis	2.82e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK3—atherosclerosis	2.82e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK3—atherosclerosis	2.78e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—atherosclerosis	2.73e-05	9.92e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—atherosclerosis	2.73e-05	9.92e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—atherosclerosis	2.73e-05	9.92e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—atherosclerosis	2.72e-05	9.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—atherosclerosis	2.71e-05	9.85e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—atherosclerosis	2.71e-05	9.85e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—atherosclerosis	2.71e-05	9.85e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—atherosclerosis	2.71e-05	9.82e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—atherosclerosis	2.7e-05	9.78e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—atherosclerosis	2.68e-05	9.71e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HMOX1—atherosclerosis	2.53e-05	9.19e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—atherosclerosis	2.51e-05	9.1e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—atherosclerosis	2.5e-05	9.06e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOB—atherosclerosis	2.43e-05	8.81e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTM1—atherosclerosis	2.36e-05	8.57e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LPL—atherosclerosis	2.32e-05	8.41e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—atherosclerosis	2.27e-05	8.25e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—atherosclerosis	2.27e-05	8.25e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—atherosclerosis	2.27e-05	8.25e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GPX1—atherosclerosis	2.26e-05	8.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—atherosclerosis	2.24e-05	8.13e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CD36—atherosclerosis	2.2e-05	7.99e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—atherosclerosis	2.09e-05	7.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—atherosclerosis	2.06e-05	7.48e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—atherosclerosis	2.06e-05	7.48e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—atherosclerosis	2.06e-05	7.48e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARA—atherosclerosis	2.05e-05	7.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—atherosclerosis	2.03e-05	7.37e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AGT—atherosclerosis	1.98e-05	7.19e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOE—atherosclerosis	1.94e-05	7.05e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CAV1—atherosclerosis	1.92e-05	6.98e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOA1—atherosclerosis	1.92e-05	6.97e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—atherosclerosis	1.9e-05	6.9e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—atherosclerosis	1.9e-05	6.9e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—atherosclerosis	1.9e-05	6.9e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—atherosclerosis	1.87e-05	6.8e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CG—atherosclerosis	1.75e-05	6.36e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARG—atherosclerosis	1.69e-05	6.14e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—INS—atherosclerosis	1.66e-05	6.02e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALB—atherosclerosis	1.52e-05	5.52e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NOS3—atherosclerosis	1.46e-05	5.28e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—atherosclerosis	1.33e-05	4.83e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—atherosclerosis	6.69e-06	2.43e-05	CbGpPWpGaD
